As of June 4, 2025, Second Sight Medical Products Inc (EYES) reports a ROE (Return on Equity) of -13.05%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Second Sight Medical Products Inc's ROE (Return on Equity)
Over recent years, Second Sight Medical Products Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -13.05% |
| 2020-12-31 | 2220.90% |
| 2019-12-31 | -461.40% |
| 2018-12-31 | -1139.29% |
| 2017-12-31 | -361.93% |
This slight downward trend highlights how Second Sight Medical Products Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Second Sight Medical Products Inc's ROE (Return on Equity) to Peers
To better understand Second Sight Medical Products Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Second Sight Medical Products Inc (EYES) | -13.05% |
| BioSig Technologies Inc (BSGM) | 694.44% |
| Avinger Inc (AVGR) | 295.39% |
| SQI Diagnostics Inc (SQD.V) | 188.78% |
| Nemaura Medical Inc (NMRD) | 119.73% |
| Acutus Medical Inc (AFIB) | 82.36% |
Compared to its competitors, Second Sight Medical Products Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.